De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Published Online: 2017-11-?
Journal: Annals of Oncology•Publisher: Elsevier BV
Authors: A. Kohls•A. Stefek•C. Liedtke•C. Schumacher•D. Augustin•E. -M. Grischke•H. Fischer•H. Forstbauer•H. Kreipe•J. Potenberg•J. Schumacher•K. Krauss•M. Braun•M. Christgen•N. Harbeck•O. Gluz•R. Kates•R. Wuerstlein•S. Kuemmel•T. Reimer•U.A. Nitz
